[1] |
LIANG Jie.
172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
|
[2] |
WANG Chunting, CHEN Yafei.
Considerations for Revision of Safety Information in the Post-Marketing Instructions of Chemical Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 776-779.
|
[3] |
LI Can, LIU Lehuan, CHEN Xia, QU Jianbo.
Pharmacy of Chinese Medicine Compound Preparations Based on Human Experiences
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 564-569.
|
[4] |
YAN Caiying, QIN Linying, XU Yaoqing, WANG Xinge, CHAI Nannan, CHEN Long.
Research Progress in Uric Acid-Lowering Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 592-595.
|
[5] |
CHEN Huan, LIANG Jun, ZHAO Wei, XIA Qingrong.
Clinical Features and Risk Factors of Liver Injury Induced by Atypical Antipsychotic Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 410-414.
|
[6] |
YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao.
A National Pharmacovigilance Management System in a New Era
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281.
|
[7] |
LIAO Mengfan, ZHONG Liling, XU Yan, LIU Ying, ZHANG Yexiang, CHEN Qingsong, LIU Xudong.
Adverse Reactions to Antihypertensive and Hypoglycaemic Drugs Based on Spontaneous Presentation Systems
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 286-291.
|
[8] |
LIU Biqing, ZHANG Xiaotong, WANG Ke, XING Xiaoxuan, WANG Zhizhou, ZHUANG Wei, ZHANG Qingxia, ZHANG Lan, LI Xiaoling, DONG Xianzhe.
Adverse Drug Reaction in 385 Elderly Inpatients with Bacterial Pneumonia under Polypharmacy
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 206-210.
|
[9] |
SHAO Bo, ZHONG Lumiao, CHENG Yuzhu, DENG Hua, ZHU Lan.
Risks to Safety of Yinhuang Oral Preparation
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 84-87.
|
[10] |
DAI Biao, CAO Yin, SUN Yanhong, ZHANG Yuanyuan, XIA Qingrong.
808 Cases of Adverse Drug Reaction Caused by Antipsychotic Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 99-103.
|
[11] |
YU Wenlu, ZHANG Hong.
Research Progress in Applications of Strychnine Semen in Orthopedics and Traumatology
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 116-120.
|
[12] |
XU Zeao, JIANG Haiyan, FAN Xiaoyu, LI Wanfang, BAO Jie, XU Cheng, JIN Hongtao.
Research progress in compound drugs for anti-neurodegenerative diseases
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 967-972.
|
[13] |
GUO Shushu, JIANG Haiyan, FAN Xiaoyu, LI Wanfang, BAO Jie, MA Enlong, JIN Hongtao.
Rationality of compound drug components against hypertension
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 973-977.
|
[14] |
SHEN Xue, JIANG Haiyan, FAN Xiaoyu, LI Wanfang, BAO Jie, HE Bosai, JIN Hongtao.
Developments in research on combination drugs for hepatic fibrosis
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 985-990.
|
[15] |
LU De, XU Wenyan, LIU Jinxin, PEI Yusheng.
Discussion and analysis of bacterial endotoxin problems in FDA warning letters
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 857-862.
|